HuGE Literature Finder
Records
1
-
10
| DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer chemotherapy and pharmacology 2017 Nov . Nahid Noor Ahmed, Apu Mohd Nazmul Hasan, Islam Md Reazul, Shabnaz Samia, Chowdhury Surid Mohammad, Ahmed Maizbha Uddin, Nahar Zabun, Islam Md Siddiqul, Islam Mohammad Safiqul, Hasnat Ab |
| Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical biochemistry 2016 Jul . Galarza Andrés Fernando Andrade, Linden Rafael, Antunes Marina Venzon, Hahn Roberta Zilles, Raymundo Suziane, da Silva Anne Caroline Cezimbra, Staggemeier Rodrigo, Spilki Fernando Rosado, Schwartsmann Gilber |
| DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013 Aug 14 (11): 1255-72. Terrazzino Salvatore, Cargnin Sarah, Del Re Marzia, Danesi Romano, Canonico Pier Luigi, Genazzani Armando |
| Contribution of the ß-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity. Pharmacological reports : PR 2012 Sep 64 (5): 5. Fidlerova J, Kleiblova P, Kormunda S, Novotny J, Kleibl Z |
| Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pacific journal of cancer prevention : APJCP 2012 13 (4): 1553-6. Dogan Mutlu, Karabulut Halil G, Tukun Ajlan, Demirkazik Ahmet, Utkan Gungor, Yalcin Bulent, Dincol Dilek, Akbulut Hakan, Icli Fik |
| Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. British journal of cancer 2011 Nov 105 (11): 1654-62. Thomas F, Motsinger-Reif A A, Hoskins J M, Dvorak A, Roy S, Alyasiri A, Myerson R J, Fleshman J W, Tan B R, McLeod H |
| The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer chemotherapy and pharmacology 2010 Jan 65 (2): 403-6. Loganayagam Aathavan, Arenas-Hernandez Monica, Fairbanks Lynette, Ross Paul, Sanderson Jeremy D, Marinaki Anthony |
| Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 2009 56 (4): 303-16. Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, Sevcik J, Novotny |
| Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 May 26 (13): 2131-8. Schwab Matthias, Zanger Ulrich M, Marx Claudia, Schaeffeler Elke, Klein Kathrin, Dippon Jürgen, Kerb Reinhold, Blievernicht Julia, Fischer Joachim, Hofmann Ute, Bokemeyer Carsten, Eichelbaum Michel, |
| The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. Avicenna journal of medical biotechnology 0 12 (3): 157-164. Abbasian Mohammad Hadi, Ansarinejad Nafiseh, Abbasi Bahareh, Iravani Masoud, Ramim Tayeb, Hamedi Fahime, Ardekani Ali |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 18, 2022
- Content source: